Dimension Therapeutics Inc (DMTX) is Initiated by Jefferies to Buy

Dimension Therapeutics Inc (DMTX) was Initiated by Jefferies to “Buy”. Jefferies advised their investors in a research report released on Jun 2, 2016.

Many Wall Street Analysts have commented on Dimension Therapeutics Inc. Dimension Therapeutics Inc was Downgraded by Goldman to ” Neutral” on Mar 30, 2016.

On the company’s financial health, Dimension Therapeutics Inc reported $-0.43 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Dec 4, 2015. Analyst had a consensus of $-0.52. The company had revenue of $2.10 million for the quarter, compared to analysts expectations of $1.73 million. The company’s revenue was up 75.0% compared to the same quarter last year.

In a different news, on Oct 29, 2015, Michael Dybbs (director) purchased 961,538 shares at $13.00 per share price.

Dimension Therapeutics Inc. is a United States-based gene therapy company focused on developing novel treatments for rare diseases. The Company is focused on developing treatments for hemophilia A hemophilia B and rare genetic diseases. The Company’s adeno-associated virus (AAV) vector technology enables for systemic administration of the gene therapy in vivo for the treatment of an array of single-gene rare diseases. The Company is conducting pre-clinical development activities for its program in hemophilia A. The Company also has access to NAV vector technology in a range of rare disease indications.

Dimension Therapeutics Inc

Leave a Reply

Dimension Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dimension Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.